Search Results for "vasodilators"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vasodilators. Results 11 to 15 of 15 total matches.

Comparison Chart: Some Drugs for HFrEF

   
The Medical Letter on Drugs and Therapeutics • May 26, 2025  (Issue 1729)
vasoactive peptides, enhances vasodilation and sodium excretion . Dose should be doubled every 2 weeks ...
View the Comparison Chart: Some Drugs for HFrEF
Med Lett Drugs Ther. 2025 May 26;67(1729):e1-15   doi:10.58347/tml.2025.1729b |  Show IntroductionHide Introduction

Zavegepant (Zavzpret) for Acute Treatment of Migraine

   
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023  (Issue 1681)
PHARMACOLOGY ― CGRP, a potent vasodilator and neurotransmitter found in the trigeminal nerve and spinal ...
The FDA has approved zavegepant nasal spray (Zavzpret – Pfizer) for acute treatment of migraine with or without aura in adults. Zavzpret is the first nasal spray formulation of a calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant") to become available in the US.
Med Lett Drugs Ther. 2023 Jul 24;65(1681):116-8   doi:10.58347/tml.2023.1681c |  Show IntroductionHide Introduction

Atogepant (Qulipta) for Migraine Prevention

   
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021  (Issue 1636)
the onset of menses.3 MECHANISM OF ACTION — CGRP is a potent vasodilator and pain-signaling ...
Atogepant (Qulipta – Abbvie), an oral small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant"), has been approved by the FDA for prevention of episodic migraine in adults. It is the second oral CGRP receptor antagonist to be approved in the US for this indication; the first was rimegepant (Nurtec ODT), which is also approved for acute treatment of migraine. Parenteral CGRP monoclonal antibodies are approved for prevention of migraine (see Table 3).
Med Lett Drugs Ther. 2021 Nov 1;63(1636):169-71 |  Show IntroductionHide Introduction

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • May 26, 2025  (Issue 1729)
– generic 5, 10, 20, 100 mg tabs 10-20 mg once/day 200 mg once/day or 41.80 in divided doses Vasodilators ...
Pharmacologic management of chronic heart failure (HF) is primarily determined by the patient's left ventricular ejection fraction (LVEF) and severity of symptoms. Patients with chronic HF who have an LVEF ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) and those with an LVEF ≥50% are considered to have heart failure with preserved ejection fraction (HFpEF). Patients with an LVEF of 41-49% have heart failure with mildly reduced or mid-range ejection fraction.
Med Lett Drugs Ther. 2025 May 26;67(1729):81-8   doi:10.58347/tml.2025.1729a |  Show IntroductionHide Introduction

Drugs for Benign Prostatic Hyperplasia

   
The Medical Letter on Drugs and Therapeutics • May 02, 2022  (Issue 1649)
additive vasodilation leading to orthostasis. Strong CYP3A4 inhibitors such as ketoconazole can increase ...
About 60% of men ≥60 years old have clinically relevant prostatic enlargement due to benign prostatic hyperplasia (BPH). The goals of treatment are to decrease lower urinary tract symptoms and to prevent disease progression and complications such as acute urinary retention. The American Urologic Association's guidelines for treatment of BPH were recently updated.
Med Lett Drugs Ther. 2022 May 2;64(1649):65-9 |  Show IntroductionHide Introduction